MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients
about
Multiwalled carbon nanotube-induced gene signatures in the mouse lung: potential predictive value for human lung cancer risk and prognosisMolecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesotheliomaMUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cellsPrediction of cancer proteins by integrating protein interaction, domain frequency, and domain interaction data using machine learning algorithms.Identification of breast cancer prognostic modules based on weighted protein-protein interaction networks.Mucin 1 C-terminal subunit oncoprotein is a target for small-molecule inhibitors.Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cellsMitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer.MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cellsDependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells.Transmembrane mucins as novel therapeutic targetsA monoclonal antibody against the oncogenic mucin 1 cytoplasmic domainCDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical CancerInhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.Smoking-induced CXCL14 expression in the human airway epithelium links chronic obstructive pulmonary disease to lung cancerAberrant Mucin5B expression in lung adenocarcinomas detected by iTRAQ labeling quantitative proteomics and immunohistochemistry.Mixed squamous cell and glandular papilloma of the lung: a case study and literature review.Anticancer property of bromelain with therapeutic potential in malignant peritoneal mesothelioma.Targeting CDKN3 in cervical cancer.Glycosylation alterations in lung and brain cancer.Update on Mucin-1 immunotherapy in cancer: a clinical perspective.MUC5AC interactions with integrin β4 enhances the migration of lung cancer cells through FAK signaling.Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.SiRNA-targeted carboxypeptidase D inhibits hepatocellular carcinoma growth.Mucin-1 correlates with survival, smoking status, and growth patterns in lung adenocarcinoma.Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cellsMUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.Glycosylation Changes in Brain Cancer.MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.Molecular Pathways: Mucins and Drug Delivery in Cancer.Development and application of a double- antibody sandwich ELISA kit for the detection of serum MUC1 in lung cancer patients.
P2860
Q23918758-D0B8B9F0-CA9B-47A3-A70D-D3F8B839C483Q28482133-888FE447-5855-4E18-9CDB-2FB033CB9C28Q28742196-76EFB0EC-D0C3-4DD4-B010-2F65133F22B3Q30930272-0940F216-05D6-4D07-A054-565B7994666CQ33697833-24029505-65B9-4D8F-AB26-0C3561317F4AQ33827824-7AF0EFDC-0ECC-4895-A0C0-E47C4DAD3936Q34449722-8D69EA9A-7374-4799-87D6-B51EFCF818DEQ34584632-042A6191-D099-45A9-8B48-84E9BF016B4DQ34619148-18A76B86-4325-46B6-A513-5DB059EF27A7Q34970672-6D60FF97-76DF-4A3C-8B0D-D0B4D5C2DA4BQ35541712-1965E422-E0A0-4DBC-8F00-97F25255A6E0Q35632645-3AA76756-CC5C-4EFA-8C5D-89F89371B5EEQ35754887-58D33FAC-79BE-43F9-97F5-F4C617C45E51Q35776083-FBE139FD-1CF8-4FDD-903F-CFA098FD51D9Q36693297-27111162-CD17-4355-9398-FB475484A933Q37297975-DEA16E27-0563-4645-806A-21CA76186F39Q37304950-251A7C60-4C41-4D9B-AA89-A7239ED2D818Q37854865-0E6D56C7-1F7C-47D3-9BE5-E0C47DB53FB4Q38097532-43DDA1D0-0DCC-4EAA-8C00-FB329AB2E4B3Q38242742-D3BFFCDF-1644-4861-99E5-144B3161D8E8Q38366332-F314486B-3F67-4571-A3C3-1DA5FF7C6EB9Q38603410-D8D7797A-36AF-4124-A3C3-9104979EFAF1Q38804960-645EC303-9E0F-4D04-97C9-BC58A31BE7BBQ39063057-A5FA58C1-E67C-4B48-AB68-A1BF1931204DQ39165661-56A115CB-4347-4E59-B570-0B13DF75CBBBQ39535574-6716F9D8-A4D2-4F3E-9270-B496C830807AQ39594994-58F5A97D-4FE3-4DB1-9986-42850810488BQ41008660-454E7430-14C6-42B5-AE6A-8A5A499C842BQ47691736-9AA204B6-6DC0-47D7-B04B-4743D7675179Q48146766-D20B6A1F-2979-43F6-866D-DE103864FFF2Q50465411-37CC95E6-A1D7-44F2-91C9-C7019F751627Q51498619-0B965B33-0050-4BA8-A7E1-11C82AB0594A
P2860
MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients
@ast
MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients
@en
MUC1-associated proliferation ...... lung adenocarcinoma patients.
@nl
type
label
MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients
@ast
MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients
@en
MUC1-associated proliferation ...... lung adenocarcinoma patients.
@nl
prefLabel
MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients
@ast
MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients
@en
MUC1-associated proliferation ...... lung adenocarcinoma patients.
@nl
P2093
P2860
P356
P1433
P1476
MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients
@en
P2093
Charles A Pelizzari
Darrin C Edwards
Dhara M MacDermed
Donald W Kufe
Nikolai N Khodarev
Sean P Pitroda
P2860
P2888
P356
10.1186/1755-8794-3-16
P577
2010-05-06T00:00:00Z
P5875
P6179
1049236808